2/4/26
While drug prices skyrocket and many Americans struggle to afford essential medications, Big Pharma gets richer and more powerful while actually delivering an ever more meagre research and development (R&D) pipeline. This paper proposes a transformational approach to the sector via a 鈥減ublic option鈥� in pharmaceutical R&D aimed at filling innovation gaps, providing competition in key market sectors and maximizing public return on public investment.